

ITONIS, INC.
A Nevada corporation
25422 Trabuco Road
Suite 105-297
Lake Forest, CA 92630

(949) 689-062
office@itonisholdings.com
SIC Code 6719

Quarterly Report

For the period ending: **November 30, 2025** (the "Reporting Period")

Preparation of these Disclosures

These Disclosures were prepared by management, or by Mark Cheung, the CEO of the Company.

Outstanding Shares

The number of shares outstanding of our Common Stock was:

1,523,409,834 as of November 30, 2025 (Current Reporting Period Date or More Recent Date)

1,523,409,834 as of November 30, 2024 (Most Recent Completed Fiscal Year End)

Shell Status

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: No:

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: No:

Change in Control

Indicate by check mark whether a Change in Control⁴ of the company has occurred during this reporting period:

Yes: No:

⁴ "Change in Control" shall mean any events resulting in:

- (i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer and names used by predecessor entities, along with the dates of the name changes.

Itonis, Inc. The company was incorporated as Kenchou, Inc. in Nevada on July 5, 2005. Name changed to Itonis, Inc. on December 2, 2005.

Current State and Date of Incorporation or Registration: Nevada, July 5, 2005

Standing in this jurisdiction: (e.g. active, default, inactive): Active.

Prior Incorporation Information for the issuer and any predecessors during the past five years: None.

Describe any trading suspension or halt orders issued by the SEC or FINRA concerning the issuer or its predecessors since inception: None.

List any stock split, dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months: None.

Address of the issuer's principal executive office: 25422 Trabuco Road, Suite 105-297, Lake Forest, California 92630.

Address of the issuer's principal place of business:

Check if principal executive office and principal place of business are the same address: _____

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No: Yes: If Yes, provide additional details below: _____

2) Security Information

Transfer Agent

Name: Securities Transfer Corp.

Phone: (469) 633-0101

Email: smith@stctransfer.com

Address: 2901 Dallas Parkway, #380, Plano, TX 75093

Publicly Quoted or Traded Securities:

The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.

Trading symbol:	<u>ITNS</u>	
Exact title and class of securities outstanding:	<u>Common</u>	
CUSIP:	<u>465733103</u>	
Par or stated value:	<u>\$0.001</u>	
Total shares authorized:	<u>1,800,000,000</u>	as of date: November 30, 2025.
Total shares outstanding:	<u>1,523,409,834</u>	as of date: November 30, 2025.
Total number of shareholders of record:	<u>662</u>	as of date: November 30, 2025.

Please provide the above-referenced information for all other publicly quoted or traded securities of the issuer. None.

Other classes of authorized or outstanding equity securities that do not have a trading symbol:

The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g., preferred shares that do not have a trading symbol). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.

Exact title and class of the security:	<u>Preferred, Series A.</u>	
Par or stated value:	<u>\$0.001</u>	
Total shares authorized:	<u>5,000,000</u>	as of date: November 30, 2025.
Total shares outstanding:	<u>500,000</u>	as of date: November 30, 2025.
Total number of shareholders of record:	<u>2</u>	as of date: November 30, 2025.

Please provide the above-referenced information for all other classes of authorized or outstanding equity securities.
None.

Security Description:

The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:

1. **For common equity, describe any dividend, voting and preemption rights.** Holders of common stock shares are entitled to vote at any meeting of stockholders as allowed by law. The corporation has not declared or authorized any dividends or preemption rights.

2. **For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.** The corporation has authorized a Series "A" Preferred Stock. The corporation has not declared or authorized any dividends or sinking fund, or any conversion or redemption rights.

Voting: Each share of Series A Preferred Stock entitles the holder to the equal to the greater of (i) One Thousand (1,000) votes for each share of Series A Preferred Stock or (ii) the number of votes equal to the number of all outstanding shares of Common Stock, plus one additional vote such that the holders of Series A Preferred Stock shall always constitute a majority of the voting rights of the corporation.

Liquidation Rights: Upon the dissolution, liquidation or winding up of the corporation, the holders of the then outstanding shares of Series A Preferred Stock shall be entitled to receive out of the assets of the corporation the sum of \$0.001 per share before any payment or distribution shall be made on any other class of capital stock of the Company ranking junior to the Series A Preferred Stock.

Conversion or Redemption: Each share of Series A Preferred Stock has no conversion or redemption rights.

Sinking Fund: None.

3. **Describe any other material rights of common or preferred stockholders.** None, no other.

4. **Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.** None.

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities in the past two completed fiscal years and any subsequent interim period.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares for the two most recently completed fiscal years and any subsequent period.

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: Yes: (If yes, you must complete the table below)

Shares Outstanding <u>Opening Balance</u> : Date <u>11/30/2017</u> Common: <u>1,523,409,834</u> Preferred: <u>500,000</u>			*Right-click the rows below and select "Insert" to add rows as needed.						
Date of Transaction	Transaction type (e.g., new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to. ***You must disclose the control person(s) for any entities listed.	Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
Shares Outstanding on Date of This Report: <u>Ending Balance</u> : Date <u>11/30/2025</u> Common: <u>1,523,409,834</u> Preferred: <u>500,000</u>									

Example: A company with a fiscal year end of December 31st 2024, in addressing this item for its Annual Report, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2023 through December 31, 2024 pursuant to the tabular format above.

Any additional material details, including footnotes to the table are below: None.

B. Convertible Debt

The following is a complete list of the Company’s Convertible Debt which includes all promissory notes, convertible notes, convertible debentures, or any other debt instruments convertible into a class of the issuer’s equity securities. The table includes all issued or outstanding convertible debt at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this Certification.

Check this box to confirm the Company had no Convertible Debt issued or outstanding at any point during this period.

Date of Note Issuance	Principal Amount at Issuance (\$)	Outstanding Balance (\$) (include accrued interest)	Maturity Date	Conversion Terms (e.g., pricing mechanism for determining conversion of instrument to shares)	# Shares Converted to Date	# of Potential Shares to be Issued Upon Conversion ⁵	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g., Loan, Services, etc.)
See Attached Chart "B".				See Attached Chart "B".			See Attached Chart "B".	

Total Outstanding Balance:

Total Shares:

Any additional material details, including footnotes to the table are below: None.

4) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. Ensure that these descriptions are updated on the Company's Profile on www.OTCMarkets.com.

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

The Company operates as a holding company and has embarked upon an aggressive plan to acquire high growth entrepreneurial companies that have established or are expected to establish themselves as leaders and successful enterprises in various market niches.

B. List any subsidiaries, parent company, or affiliated companies. Subsidiaries: Itonis Holdings, Inc., Itonis Pharmaceuticals, and Paramount Discoveries, Inc.

C. Describe the issuers' principal products or services.

In 2012, the Company launched a new Itonis Pharmaceuticals division to produce and market over the counter and prescription homeopathic preparations to treat both common ailments and chronic diseases. The Company has launched the retail sale of the Emesyl® nausea relief product. The Company has identified the market for its Emesyl® product line as the general public who suffers from nausea. Emesyl® has been available for purchase at <https://www.amazon.com/dp/B00U20H3KI> and www.Emesyl.com.

The Company's Itonis Holdings, Inc. subsidiary owns and manages the entirety of the Emesyl® nausea relief product line by full assignment of all the patent rights in Emesyl® nausea relief from the inventor. The Company has organized said Itonis Pharmaceuticals division and its Emesyl® and Emesyl® Product line within its wholly-owned subsidiary, Itonis Holdings, Inc.

On or about March 28, 2023, the Company transferred its Emesyl Plus product to Smart Cannabis Inc. in exchange for 147,000,000 shares of Smart Cannabis, Inc's common stock.

⁵ The total number of shares that can be issued upon full conversion of the Outstanding Balance. The number should not factor any "blockers" or limitations on the percentage of outstanding shares that can be owned by the Noteholder at a particular time. For purposes of this calculation, please use the current market pricing (e.g. most recent closing price, bid, etc.) of the security if conversion is based on a variable market rate.

5) Issuer's Facilities

The goal of this section is to provide investors with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer. Describe the location of office space, data centers, principal plants, and other property of the issuer and describe the condition of the properties. Specify if the assets, properties, or facilities are owned or leased and the terms of their leases. If the issuer does not have complete ownership or control of the property, describe the limitations on the ownership.

None. Issuer is in the process of locating new facilities.

6) All Officers, Directors, and Control Persons of the Company

Using the table below, please provide information, as of the period end date of this report, regarding all officers and directors of the company, or any person that performs a similar function, regardless of the number of shares they own.

In addition, list all individuals or entities controlling 5% or more of any class of the issuer's securities.

If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity. Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

The goal of this section is to provide investors with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial owners.

Individual Name (First, Last) or Entity Name (Include names of control person(s) if a corporate entity)	Position/Company Affiliation (ex: CEO, 5% Control person)	City and State (Include Country if outside U.S.)	Number of Shares Owned (List common, preferred, warrants and options separately)	Class of Shares Owned	Percentage of Class of Shares Owned (undiluted)
Mark Cheung	CEO, CFO, Secretary, Director	Lake Forest, CA	<u>179,458,875</u> <u>250,000</u>	Common Preferred	<u>11.8%</u> <u>50%</u>
<u>Steve Pidliskey</u>	<u>>5%</u>	<u>Lake Forest, CA</u>	<u>99,948,668</u>	<u>Common</u>	<u>6.6%</u>
<u>Sam Joudeh</u>	<u>Director</u>	<u>Lake Forest, CA</u>	<u>3,000,000</u> <u>250,000</u>	<u>Common</u> <u>Preferred</u>	<u>0.2%</u> <u>50%</u>

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, log in to www.OTCIQ.com to update your company profile.

7) Legal/Disciplinary History

A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations); None.

2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities; None.
3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated; None.
4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or None.
5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities. None.
6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail. None.

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party to or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities. None.

8) Third Party Service Providers

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, update your company profile.

Securities Counsel

Name: Mark Cheung
 Address 1: 25422 Trabuco Road, Suite 105-297
 Address 2: Lake Forest, CA 92630
 Phone: _____
 Email: markcheung@msn.com

Accountant or Auditor

Name: Jill Twombly (MBA)
 Firm: _____
 Address 1: _____
 Address 2: _____
 Phone: _____
 Email: _____

Investor Relations

Name: None.

Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

All other means of Investor Communication: None.

X (Twitter): _____
Discord: _____
LinkedIn _____
Facebook: _____
[Other] _____

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement.** This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name: None.
Firm: _____
Nature of Services: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

9) Disclosure & Financial Information

A. This Disclosure Statement was prepared by (name of individual):

Name: Mark Cheung
Title: CEO
Relationship to Issuer: CEO

B. The following financial statements were prepared in accordance with:

- IFRS
 U.S. GAAP

C. The following financial statements were prepared by (name of individual):

Name: Jill Twombly
Title: Accountant
Relationship to Issuer: Outside retained accountant

Describe the qualifications of the person or persons who prepared the financial statements:⁶ Jill Twombly has an MBA degree in Finance, has over 30 years of experience in corporate accounting and public company financials.

⁶ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

Provide the following qualifying financial statements:

- Audit letter, if audited;
- Balance Sheet;
- Statement of Income;
- Statement of Cash Flows;
- Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- Financial Notes

Financial Statement Requirements:

- Financial statements must be published together with this disclosure statement as one document.
- Financial statements must be “machine readable”. Do not publish images/scans of financial statements.
- Financial statements must be presented with comparative financials against the prior FYE or period, as applicable.
- Financial statements must be prepared in accordance with U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited.

10) Issuer Certification

Principal Executive Officer and Chief Financial Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Mark Cheung, certify that:

1. I have reviewed this Disclosure Statement for Itonis, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

February 28, 2026 [Date]

/s/ Mark Cheung [CEO's & CFO's Signature]

(Digital Signatures should appear as “/s/ [OFFICER NAME]”)

CHART "B" -- ITNS Promissory Notes Schedule November 30, 2025

Date of Note Issuance	Principal Amount at Issuance (\$)	Outstanding Balance with Interest (\$)	Maturity Date	Conversion Terms	# Shares Converted to Date	# Potential Shares to be Issued Upon Conversion	Name of Noteholder	Reason for Issuance
7/31/2013	\$15,000.00	\$24,000.00	1/31/2014	Conversion at 75% of trading share price.	Zero	240,000,000	Abraham Abu	Loan
7/31/2013	\$8,500.00	\$13,600.00	7/31/2014	Conversion at 75% of trading share price.	Zero	136,000,000	CZA Inc (Doris Vo)	Loan
8/13/2013	\$2,000.00	\$3,200.00	8/13/2014	Conversion at 75% of trading share price.	Zero	32,000,000	CZA Inc (Doris Vo)	Loan
10/31/2013	\$2,800.00	\$4,480.00	5/31/2014	Conversion at 75% of trading share price.	Zero	44,800,000	Doris Vo	Loan
10/31/2013	\$31,250.00	\$50,000.00	5/31/2014	Conversion at 75% of trading share price.	Zero	500,000,000	Mark Cheung	Loan
11/30/2013	\$12,500.00	\$20,000.00	5/31/2014	Conversion at 75% of trading share price.	Zero	200,000,000	CZA Inc (Doris Vo)	Loan
2/28/2014	\$11,000.00	\$17,600.00	8/31/2014	Conversion at 75% of trading share price.	Zero	176,000,000	CZA Inc (Doris Vo)	Loan
5/31/2014	\$35,000.00	\$56,000.00	11/30/2014	Conversion at 75% of trading share price.	Zero	560,000,000	CZA Inc (Doris Vo)	Loan
6/30/2014	\$150,000.00	\$162,401.21	12/31/2014	Conversion at 75% of trading share price.	Zero	1,624,012,100	CZA Inc (Doris Vo)	Loan
8/31/2014	\$81,000.00	\$93,456.12	2/28/2015	Conversion at 75% of trading share price.	Zero	934,561,200	CZA Inc (Doris Vo)	Loan
11/30/2014	\$10,000.00	\$15,000.00	5/31/2015	Conversion at 75% of trading share price.	Zero	150,000,000	CZA Inc (Doris Vo)	Loan
2/18/2015	\$13,500.00	\$20,250.00	8/31/2015	Conversion at 75% of trading share price.	Zero	202,500,000	CZA Inc (Doris Vo)	Loan
3/31/2015	\$100,000.00	\$113,998.34	9/30/2015	Conversion at 75% of trading share price.	Zero	1,139,983,400	Doris Vo	Loan

4/30/2015	\$4,200.00	\$6,300.00	10/31/2015	Conversion at 75% of trading share price.	Zero	63,000,000	Doris Vo	Loan
5/31/2015	\$54,500.00	\$69,821.63	11/30/2015	Conversion at 75% of trading share price.	Zero	698,216,300	CZA Inc (Doris Vo)	Loan
8/31/2015	\$15,000.00	\$18,000.00	8/31/2016	Conversion at 75% of trading share price.	Zero	180,000,000	CZA Inc (Doris Vo)	Loan
11/30/2015	\$14,000.00	\$16,800.00	11/30/2016	Conversion at 75% of trading share price.	Zero	168,000,000	CZA Inc (Doris Vo)	Loan
12/31/2015	\$550.00	\$660.00	12/31/2016	Conversion at 75% of trading share price.	Zero	6,600,000	Mark Cheung	Loan
2/29/2016	\$1,860.00	\$2,232.00	2/29/2017	Conversion at 75% of trading share price.	Zero	22,320,000	Abraham Abu	Loan
2/29/2016	\$21,500.00	\$25,800.00	2/29/2017	Conversion at 75% of trading share price.	Zero	258,000,000	CZA Inc (Doris Vo)	Loan
5/31/2016	\$19,000.00	\$22,800.00	5/31/2017	Conversion at 75% of trading share price.	Zero	228,000,000	CZA Inc (Doris Vo)	Loan
5/31/2016	\$900.00	\$1,080.00	5/31/2017	Conversion at 75% of trading share price.	Zero	10,800,000	Mark Cheung	Loan
8/31/2016	\$28,000.00	\$33,600.00	8/31/2017	Conversion at 75% of trading share price.	Zero	336,000,000	CZA Inc (Doris Vo)	Loan
8/31/2016	\$9,999.96	\$11,999.95	8/31/2017	Conversion at 75% of trading share price.	Zero	119,999,520	Abraham Abu	Loan
11/30/2016	\$7,011.99	\$8,414.39	5/31/2017	Conversion at 75% of trading share price.	Zero	84,143,880	Abraham Abu	Loan
11/30/2016	\$16,600.00	\$19,920.00	5/31/2017	Conversion at 75% of trading share price.	Zero	199,200,000	CZA Inc (Doris Vo)	Loan
2/28/2017	\$4,023.98	\$4,828.78	8/31/2017	Conversion at 75% of trading share price.	Zero	48,287,760	Abraham Abu	Loan
2/28/2017	\$7,500.00	\$9,000.00	8/31/2017	Conversion at 75% of trading share price.	Zero	90,000,000	CZA Inc (Doris Vo)	Loan
5/31/2017	\$24,000.00	\$28,800.00	11/30/2017	Conversion at 75% of trading share price.	Zero	288,000,000	CZA Inc (Doris Vo)	Loan

8/31/2017	\$18,500.00	\$22,200.00	2/28/2018	Conversion at 75% of trading share price.	Zero	222,000,000	CZA Inc (Doris Vo)	Loan
11/30/2017	\$24,800.00	\$29,760.00	5/31/2018	Conversion at 75% of trading share price.	Zero	297,600,000	CZA Inc (Doris Vo)	Loan
2/28/2018	\$12,000.00	\$14,400.00	8/30/2018	Conversion at 75% of trading share price.	Zero	144,000,000	Charlie Abujudeh	Loan
4/30/2018	\$3,760.31	\$4,512.37	10/31/2018	Conversion at 75% of trading share price.	Zero	45,123,720	Charlie Abujudeh	Loan
5/31/2018	\$42,000.00	\$50,400.00	11/30/2018	Conversion at 75% of trading share price.	Zero	504,000,000	Charlie Abujudeh	Loan
6/30/2018	\$5,882.00	\$7,058.40	12/31/2018	Conversion at 75% of trading share price.	Zero	70,584,000	Abraham Abu	Loan
8/31/2018	\$5,000.00	\$6,000.00	3/31/2019	Conversion at 75% of trading share price.	Zero	60,000,000	Charlie Abujudeh	Loan
10/31/2018	\$1,800.00	\$2,160.00	4/30/2019	Conversion at 75% of trading share price.	Zero	21,600,000	Mark Cheung	Loan
11/30/2018	\$13,200.00	\$15,840.00	5/31/2019	Conversion at 75% of trading share price.	Zero	158,400,000	Charlie Abujudeh	Loan
2/28/2019	\$13,500.00	\$14,850.00	8/31/2019	Conversion at \$0.001/share.	Zero	14,850,000	Charlie Abujudeh	Loan
5/31/2019	\$17,000.00	\$18,700.00	11/30/2019	Conversion at \$0.001/share.	Zero	18,700,000	Intermarket Associates (control Charlie Abujudeh)	Loan
8/31/2019	\$12,000.00	\$13,200.00	2/29/2020	Conversion at \$0.001/share.	Zero	13,200,000	Intermarket Associates (control Charlie Abujudeh)	Loan
11/30/2019	\$10,000.00	\$11,002.06	5/31/2020	Conversion at \$0.001/share.	Zero	11,002,060	Intermarket Associates (control Charlie Abujudeh)	Loan

2/28/2020	\$13,514.90	\$14,866.39	8/31/2020	Conversion at \$0.001/share.	Zero	14,866,390	Intermarket Associates (control Charlie Abujudeh)	Loan
8/31/2020	\$14,800.00	\$16,280.00	2/29/2021	Conversion at \$0.001/share.	Zero	16,280,000	Intermarket Associates (control Charlie Abujudeh)	Loan
11/30/2020	\$11,500.00	\$12,650.00	5/31/2021	Conversion at \$0.001/share.	Zero	12,650,000	Intermarket Associates (control Charlie Abujudeh)	Loan
2/28/2021	\$9,000.00	\$9,900.00	2/28/2022	Conversion at 50% of trading share price.	Zero	9,900,000	CZA Inc (Doris Vo)	Loan
2/28/2021	\$3,000.00	\$3,300.00	2/28/2022	Conversion at \$0.001/share.	Zero	3,300,000	Intermarket Associates (control Charlie Abujudeh)	Loan
5/31/2021	\$13,000.00	\$14,300.00	5/31/2022	Conversion at \$0.001/share.	Zero	14,300,000	Intermarket Associates (control Charlie Abujudeh)	Loan
6/30/2021	\$5,000.00	\$5,550.00	6/30/2022	Conversion at \$0.001/share.	Zero	5,550,000	Intermarket Associates (control Charlie Abujudeh)	Loan
11/30/2021	\$10,000.00	\$11,051.00	11/30/2022	Conversion at \$0.001/share.	Zero	11,051,000	Mark Cheung	Loan
11/30/2022	\$33,913.04	\$37,304.34	11/30/2023	Conversion at \$0.001/share.	Zero	37,304,344	Mark Cheung	Loan
2/28/2023	\$9,590.00	\$10,549.00	2/28/2024	Conversion at \$0.001/share.	Zero	10,549,000	Mark Cheung	Loan
5/31/2023	\$12,630.00	\$13,893.00	5/31/2024	Conversion at \$0.001/share.	Zero	13,893,000	Mark Cheung	Loan
8/31/2023	\$14,007.10	\$15,407.81	8/31/2024	Conversion at \$0.001/share.	Zero	15,407,810	Mark Cheung	Loan
11/30/2023	\$1,940.93	\$2,135.02	11/30/2024	Conversion at \$0.001/share.	Zero	2,135,023	Mark Cheung	Loan
2/26/2023	\$500.00	\$550.00	2/26/2024	Conversion at \$0.001/share.	Zero	550,000	Mark Cheung	Loan

5/31/2024	\$1,975.70	\$2,114.00	5/31/2025	Conversion at \$0.001/share.	Zero	2,113,999	Mark Cheung	Loan
8/30/2024	\$2,645.22	\$2,777.48	8/30/2025	Conversion at \$0.001/share.	Zero	2,777,481	Mark Cheung	Loan
11/29/2024	\$7,204.00	\$7,564.20	11/29/2025	Conversion at \$0.001/share.	Zero	7,564,200	Mark Cheung	Loan
5/30/2025	\$850.00	\$942.50	5/30/2026	Conversion at \$0.001/share.	Zero	942,500	Mark Cheung	Loan
8/31/2025	\$8,100.00	\$8,150.00	8/31/2026	Conversion at \$0.001/share.	Zero	8,150,000	Mark Cheung	Loan
11/26/2025	\$799.00	\$799.00	11/26/2026	Conversion at \$0.001/share.	Zero	799,000	Mark Cheung	Loan
Totals:	\$1,054,608.13	\$1,274,209.00				10,511,567,687		

Itonis, Inc. (fka "Kenshou, Inc.")
Balance Sheet Unaudited Prev Year Comparison
As of November 30, 2025

	Nov 30, 25	Nov 30, 24	\$ Change	% Change
ASSETS				
Current Assets				
Checking/Savings				
Cash	391.70	1,764.00	-1,372.30	-77.8%
Total Checking/Savings	391.70	1,764.00	-1,372.30	-77.8%
Other Current Assets				
Emesyl Patent	13,000.00	13,000.00	0.00	0.0%
Other Assets	119,686.00	119,686.00	0.00	0.0%
Total Other Current Assets	132,686.00	132,686.00	0.00	0.0%
Total Current Assets	133,077.70	134,450.00	-1,372.30	-1.02%
Other Assets				
Inventory	3,324.00	3,324.00	0.00	0.0%
Total Other Assets	3,324.00	3,324.00	0.00	0.0%
TOTAL ASSETS	136,401.70	137,774.00	-1,372.30	-1.0%
LIABILITIES & EQUITY				
Liabilities				
Current Liabilities				
Other Current Liabilities				
Accounts Payable - Related Part	229,249.00	229,249.00	0.00	0.0%
Derivative Liability	1,800.00	1,800.00	0.00	0.0%
Income Tax Payable	5,600.00	5,600.00	0.00	0.0%
Loan Payable	1,044,960.00	1,035,010.00	9,950.00	0.96%
Total Other Current Liabilities	1,281,609.00	1,271,659.00	9,950.00	0.78%
Total Current Liabilities	1,281,609.00	1,271,659.00	9,950.00	0.78%
Total Liabilities	1,281,609.00	1,271,659.00	9,950.00	0.78%
Equity				
Common Stock	1,523,410.00	1,523,410.00	0.00	0.0%
Common Stock Smart Cannibus	117,600.00	117,600.00	0.00	0.0%
Paid in Capital	13,441,157.00	13,441,157.00	0.00	0.0%
Preferred Stock	500.00	500.00	0.00	0.0%
Retained Earnings	-16,216,552.05	-16,216,552.05	0.00	0.0%
Net Income	-11,322.25	0.00	-11,322.25	-100.0%
Total Equity	-1,145,207.30	-1,133,885.05	-11,322.25	-1.0%
TOTAL LIABILITIES & EQUITY	136,401.70	137,773.95	-1,372.25	-1.0%

Itonis, Inc. (fka "Kenshou, Inc.")
Profit & Loss Unaudited Prev Year Comparison
December 2024 through November 2025

	<u>Dec '24 -Nov '25</u>	<u>Dec '23 - Nov 24</u>	<u>\$ Change</u>	<u>% Change</u>
Ordinary Income/Expense				
Income				
Revenue - Emesyl	152.69	344.00	-191.31	-55.61%
Total Income	<u>152.69</u>	<u>344.00</u>	<u>-191.31</u>	<u>-55.61%</u>
Cost of Goods Sold				
Cost of Goods	0.00	0.00	0.00	0.0%
Total COGS	<u>0.00</u>	<u>0.00</u>	<u>0.00</u>	<u>0.0%</u>
Gross Profit	152.69	344.00	-191.31	-55.61%
Expense				
General & Administrative Expens	11,474.94	9,972.00	1,502.94	15.07%
Total Expense	<u>-11,322.25</u>	<u>-9,628.00</u>	<u>-1,694.25</u>	<u>-17.6%</u>
Net Ordinary Income				
Other Income/Expense				
Other Expense				
(Gain) Loss on Derivative Liabi	0.00	0.00	0.00	0.0%
Total Other Expense	<u>0.00</u>	<u>0.00</u>	<u>0.00</u>	<u>0.0%</u>
Net Other Income	0.00	0.00	0.00	0.0%
Net Income	<u><u>-11,322.25</u></u>	<u><u>-9,628.00</u></u>	<u><u>-1,694.25</u></u>	<u><u>-17.6%</u></u>

Itonis, Inc. (fka "Kenshou, Inc.")
Unaudited Statement of Cash Flows
December 2024 through November 2025
prev year comparison

	<u>Dec '24 -Nov '25</u>	<u>Dec '23 - Nov '24</u>	<u>\$ Change</u>	<u>% Change</u>
OPERATING ACTIVITIES				
Net Income	-11,322.25	-9,628.00	(1,694.25)	17.6%
Other Assets	0.00	0.00	0.00	100.0%
Net cash provided by Operating Activities	-11,322.25	-9,628.00		
INVESTING ACTIVITIES				
Loan Payable	9,950.00	124,569.00	(114,619.00)	100.0%
Net cash provided by Investing Activities	9,950.00	124,569.00		
FINANCING ACTIVITIES				
Common Stock Smart Cannabis	0.00	0.00	0.00	100.0%
Paid in Capital	0.00	-113,620.00	113,620.00	-100.0%
Net cash provided by Financing Activities	0.00	-113,620.00	113,620.00	-100.0%
Net cash increase for period	-1,372.25	1,321.00	(2,693.25)	-203.9%
Cash at beginning of period	1,764.00	443.00	1,321.00	298.2%
Cash at end of period	<u>391.75</u>	<u>1,764.00</u>	<u>(1,372.25)</u>	<u>-77.8%</u>

Itonis, Inc. (fka "Kenshou Inc.")
Statement of Stockholders Equity
November 30, 2025
Unaudited

	Preferred Stock		Common Shares		Paid In Capital	Accum Earnings	Total Stockholders Equity
	Shares	Amount	Shares	Amount			
Balance 11/30/21	500,000	500	1,523,409,834	1,523,410	13,513,059	(16,161,038)	(1,124,069)
Net Income(loss) 2/28/22						(2,211)	(2,211)
Net Income(loss) 05/31/22					1,500	(1,030)	470
Net Income(loss) 8/31/22					1,200	(2,327)	(1,127)
Net Income(loss) 11/30/22					1,000	(2,005)	(1,005)
11/30/2022	500,000	500	1,523,409,834	1,523,410	13,516,759	(16,168,611)	(1,127,942)
Net Income(loss) 2/28/23			147,000	294,000	9,440	(9,491)	293,949
Net Income(loss) 05/31/23				-220,500	12,630	(12,184)	(220,054)
Net Income(loss) 8/31/23				73,500	14,007	(14,134)	73,373
Net Income(loss) 11/30/23				-73,500	1,941	(2,504)	(74,063)
11/30/2023	500,000	500	1,523,556,834	1,596,910	13,554,777	-16,206,924	(1,054,737)
Net Income(loss) 2/29/24					500	(522)	(22)
Net Income(loss) 05/31/24					(123,969)	(628)	(124,597)
Net Income(loss) 8/31/24					2,645	(664)	1,981
Net Income(loss) 11/30/24				44,100	7,204	(7,814)	43,490
11/30/2024	500,000	500	1,523,556,834	1,641,010	13,441,157	-16,216,552	(1,133,885)
Net Income(loss) 2/28/25						(672)	(672)
Net Income(loss) 05/31/25						(741)	(741)
Net Income(loss) 8/31/25						(8,658)	(8,658)
Net Income(loss) 11/30/25						(1,251)	(1,251)
11/30/2025	500,000	500	1,523,556,834	1,641,010	13,441,157	-16,227,874	(1,145,207)

Itonis Inc.
(Formerly "Kenshou Inc.")
Notes to the Financial Statements
(unaudited)

NOTE 1. DESCRIPTION OF BUSINESS AND ACCOUNTING POLICIES

Description of Business – Itonis, Inc. (formerly Kenshou Inc.) (the "Company" or "Itonis") was incorporated on July 5, 2005 as Kenshou Inc. under the laws of the State of Nevada. On December 2, 2005, the Company changed its name to Itonis Inc.

In 2012, the Company launched a new Itonis Pharmaceuticals division to produce and market over the counter and prescription homeopathic preparations to treat both common ailments and chronic diseases. The Company has launched the retail sale of the Emesyl® nausea relief product. The Company has identified the market for its Emesyl® product line as the general public who suffers from nausea. The Emesyl® product is available for purchase online.

Since then, the Company has organized its Itonis Holdings, Inc. subsidiary to own and manage the entirety of the Emesyl® nausea relief product line. The inventor has fully assigned all the patent rights in Emesyl® nausea relief to Itonis Holdings, Inc.

Use of Estimates and Assumptions - The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Basis of Presentation - These financial statements present the balance sheets and the related statements of operations, cash flows and stockholders' deficit of Itonis, Inc.

Fiscal Periods – The Company's fiscal year-end is November 30.

Cash and Cash Equivalents - For the purpose of the statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents. The carrying value of these investments approximates fair value.

Itonis Inc.
(Formerly “Kenshou Inc.”)
Notes to the Financial Statements
(unaudited)

Inventory- The Company has capitalized product costs related to Emesyl™ which are written off as product is sold.

Patent- The Company acquired all rights to the patent for Emesyl™.

Accounts Payable-Related parties- Amounts have been advanced by related parties to fund the operations of the Company. The advances are non-interest bearing, unsecured, and due on demand.

Income Taxes - The Company accounts for its income taxes in accordance with FASB Codification Topic ASC 740-10, “*Income Taxes*”, which requires recognition of deferred tax assets and liabilities for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Earnings (loss) Per Share - The Company reports earnings (loss) per share in accordance with FASB Codification Topic ASC 260-10 “*Earnings Per Share*”, Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted earnings (loss) per share has not been presented since the effect of the assumed exercise of options and warrants to purchase common shares (common stock equivalents) would have an anti-dilutive effect.

Fair Value of Financial Instruments - Accounting Standards Codification (“ASC”) 820, Fair Value Measurements and Disclosures, requires disclosing fair value to the extent practicable for financial instruments that are recognized or unrecognized in the balance sheet. Fair value of financial instruments is the amount at which the instruments could be exchanged in a current transaction between willing parties. The Company considers the carrying amounts of cash, certificates of deposit, accounts receivable, accounts payable, notes payable, related party and other payables, customer deposits, and short term loans to approximate their fair values because of the short period of time between the origination of such instruments and their expected realization. The Company considers the carrying amounts of notes payable to approximate their fair values

Itonis Inc.
(Formerly “Kenshou Inc.”)
Notes to the Financial Statements
(unaudited)

based on the interest rates of the instruments and the current market rate of interest.

Recent Accounting Pronouncements-

Company management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements.

NOTE 2. GOING CONCERN

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Under current operations the Company requires capital for its operational and marketing activities to take place. The Company’s ability to raise additional capital through the future issuances of common stock is unknown. Obtaining additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts of and classification of liabilities that might be necessary in the event the company cannot continue in existence

NOTE 3. RELATED PARTY TRANSACTIONS

Management of the Company has made non-interest bearing, unsecured, due on demand cash advances and loans to the Company and has accrued amounts due an officer for services which total \$229,249 as of the end of this Reporting Period.

NOTE 4. LOANS PAYABLE

Through this Reporting Period, the Company had received short-term loans from related parties that are itemized in the accompanying Quarterly Report tables.

Itonis Inc.
(Formerly “Kenshou Inc.”)
Notes to the Financial Statements
(unaudited)

NOTE 5. STOCKHOLDERS’ DEFICIT

Preferred Stock:

The Company has authorized 5,000,000 shares of preferred stock

On June 4, 2012, the Board of Directors of the Company approved the designation of Series A preferred shares which provides voting rights equal to the greater of (i) One Thousand (1,000) votes for each share of Series A Preferred Stock or (ii) the number of votes equal to the number of all outstanding shares of Common Stock, plus one additional vote such that the holders of Series A Preferred Stock shall always constitute a majority of the voting rights of the Corporation.

500,000 shares of Preferred Shares were issued to related parties June 5, 2015.

Common Stock:

On July 6, 2015 shareholders of record holding over 50% of the issued and outstanding shares of the Company approved the increase in authorized shares from 1,000,000,000 to 1,800,000,000 shares. There were 1,523,409,834 shares of common stock outstanding as of this Reporting Period.

Share Transactions:

Common Stock

There were no Common Stock share transactions during 2023, 2024 and through this Reporting Period in 2025.

NOTE 6. INCOME TAXES

Deferred tax assets are comprised of the benefits of loss carry forwards for the periods through November 30, 2021 are approximately \$350,000. Losses prior to December 1, 2009 were incurred in different industries and in foreign jurisdictions and their use would be limited to offset federal and state income taxes. These losses would also be limited by the change of control provisions in Section 382 and 383 of the Internal Revenue Code.

Itonis Inc.
(Formerly “Kenshou Inc.”)
Notes to the Financial Statements
(unaudited)

Management has concluded that the use of these loss carry forwards would be severely restricted and the effect of these losses is not included in this report.

Deferred taxes arise from temporary differences in the recognition of certain expenses for tax and financial reporting purposes. As of this Reporting Period, the company had significant timing differences for tax reporting purposes for the non-cash recognition of liabilities due for committed shares in excess of authorized shares, shares issued for services, and shares issued for compensation. The expenses related to these liabilities are treated as permanent differences between financial and tax reporting.

As of this Reporting Period, management determined that realization of these loss carry forward benefits is not assured and has provided a valuation allowance for the entire amount of such benefits,

ASC 740 clarifies the accounting for uncertainty in income taxes and prescribes a recognition threshold, measurement attribute for the financial statement recognition and measurement of a tax position taken, or expected to be taken, in a tax return. Under ASC 740, we are required to recognize in the financial statements the impact of a tax position, if that position is more likely than not of being sustained on audit, based on the technical merits of the position. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods and disclosure. Our policy is to record interest and penalties related to unrecognized tax benefits in income tax expense. There were no unrecognized tax benefits recorded as of this Reporting Period.